Market Place
Sourcing Support
Relief Announces Six-Month Stability Data on a New Formulation of RLF-100
07 Nov 2022 //
ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on RLF-100(R)
03 Aug 2022 //
ACCESSWIRE
Déjà vu: FDA rejects NRx filing for emergency use in COVID-19
02 Jul 2022 //
FIERCEBIOTECH
NRx Pharma Provides Update on BTD Request for ZYESAMI
10 Jun 2022 //
PRNEWSWIRE
NRx to halt analysis of Zyesami for critical Covid-19 due to futility
27 May 2022 //
CLINICALTRIALSARENA
NRx tanks as peptide fails NIH trial in severe COVID-19 patients
27 May 2022 //
FIERCEBIOTECH
NRx Pharma Files New Breakthrough Therapy Designation Request for ZYESAMI®
21 Apr 2022 //
PRNEWSWIRE
I-SPY COVID Trial Suggests No Benefit with Addition of Nebulized ZYESAMI
31 Mar 2022 //
PRNEWSWIRE
NRx Pharma Expand ZYESAMI US Access and Right to Try Programs
18 Jan 2022 //
GLOBENEWSWIRE
NRx seeks breakthrough therapy designation for Covid-19 treatment
29 Dec 2021 //
PHARMACEUTICAL-TECHNOLOGY
NRx provides encouraging safety data of Zyesami in Covid-19 trial
15 Dec 2021 //
CLINICALTRIALSARENA
NRx Announces New, Favorable Safety Report for ZYESAMI® (aviptadil)
14 Dec 2021 //
GLOBENEWSWIRE
NRx Pharmaceuticals Identifies Significantly Higher Likelihood
29 Nov 2021 //
GLOBENEWSWIRE
NRx Pharmaceuticals Receives FDA Review of ZYESAMI Manufacturing Information
11 Nov 2021 //
GLOBENEWSWIRE
US Food and Drug Administration Declines Emergency Use Authorization ZYESAMI®
04 Nov 2021 //
PRNEWSWIRE
NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI®
02 Nov 2021 //
PRNEWSWIRE
NRx Pharma up 35% on supply arrangement for Zyesami
12 Oct 2021 //
SEEKINGALPHA
NRx Pharma Announces Progress on Worldwide Commercial Scale DevP of ZYESAMI™
12 Oct 2021 //
PRNEWSWIRE
Study finds NRx’s Zyesami boosts survival in comorbid Covid-19 patients
28 Sep 2021 //
CLINICALTRIALSARENA
NRx Pharma Announces Positive Data for ZYESAMI (aviptadil)
27 Sep 2021 //
PRNEWSWIRE
Relief Therapeutics Provides Update on Regulatory Interactions in the UK
13 Sep 2021 //
PRESS RELEASE
NRx Pharma provides positive safety update on Zyesami in Phase 3 study
20 Aug 2021 //
PHARMABIZ
NRx Starts Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAM
07 Jul 2021 //
PR NEWSWIRE
NRx Starts Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAM
07 Jul 2021 //
PR NEWSWIRE
Biophore applies for DCGI approval for EU of Aviptadil to treat COVID-19
10 Jun 2021 //
EXPRESS PHARMA
Relief Confirms Release of 60-Day Findings from Ph 2b/3 Clinical Trial RLF-100™
30 Mar 2021 //
BIOSPACE
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10
24 Feb 2021 //
PRNEWSWIRE
NeuroRx’s Zyesami accelerates recovery in Covid-19 trial
24 Feb 2021 //
CLINICALTRIALSARENA
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day
23 Feb 2021 //
PRNEWSWIRE
NeuroRx reports Initial Phase 2b/3 Study Results Benefit of ZYESAMI™
09 Feb 2021 //
PRNEWSWIRE
NeuroRx Initiates Ph2/3 Study of Inhaled ZYESAMI™ for COVID-19 UCI Health
03 Feb 2021 //
PRNEWSWIRE
NeuroRx & Relief announce topline efficacy data from patients treated RLF-100™
15 Oct 2020 //
PRNEWSWIRE
Relief Therapeutics announces supply deals while awaiting COVID-19 trial data
30 Sep 2020 //
REUTERS
Relief Announces Capital Increase from its Final Tranche
27 Sep 2020 //
BIOSPACE
NeuroRx requests emergency use of RLF-100 in COVID-19
22 Sep 2020 //
SEEKING ALPHA
FDA Grants Inhaled Use IND for RLF-100 (Aviptadil) to Treat Patients Moderate
05 Aug 2020 //
BUSINESSWIRE
New drug RLF-100 shows dramatic recovery in COVID-19 patients suffering
05 Aug 2020 //
INDIATIMES
Relief ’ aviptadil gets US FDA expanded access protocol respiratory failure
29 Jul 2020 //
PHARMABIZ
US FDA grants fast track status to Aviptadil to treat respiratory distress
28 Jun 2020 //
PHARMABIZ
FDA grants fast track status to NeuroRx’s Covid-19 drug candidate
23 Jun 2020 //
PHARMACEUTICAL-TECHNOLOGY
Relief Therapeutics & NeuroRx Expand Clinical Trial of RLF-100 to All Patients
09 Jun 2020 //
GLOBENEWSWIRE
Relief Therapeutics Announces Filing of IND for Ph2/3 Trial of Inhaled RLF-100
11 May 2020 //
GLOBENEWSWIRE
Relief Therapeutics studies Aviptadil for Covid-19-related ARDS
06 May 2020 //
CLINICALTRIALSARENA
RELIEF THERAPEUTICS & NeuroRx File FDA IND for Aviptadil to Treat COVID-19
26 Mar 2020 //
PRNEWSWIRE
RELIEF THERAPEUTICS & NeuroRx File FDA IND for Aviptadil to Treat COVID-19
26 Mar 2020 //
PRNEWSWIRE
RELIEF THERAPEUTICS Holding SA Announces an Out-Licensing Agreement with H&H Group
13 Sep 2018 //
BUSINESSWIRE
